Basilea Pharmaceutica's ROE % for the quarter that ended in Dec. 2025 was 42.30%. Basilea Pharmaceutica's PB Ratio for the quarter that ended in Dec. 2025 was 5.26.
Basilea Pharmaceutica's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 8.04%.
Basilea Pharmaceutica ROE % Adjusted to Book Value Related Terms
Basilea Pharmaceutica ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica ROE % Adjusted to Book Value Chart
XSWX:BSLN vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 8.04% mean?
Basilea Pharmaceutica (XSWX:BSLN) has a ROE % Adjusted to Book Value of 8.04% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's ROE % Adjusted to Book Value too high?
Basilea Pharmaceutica's current ROE % Adjusted to Book Value is 8.04%. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's ROE % Adjusted to Book Value compare to VRTX and REGN?
Basilea Pharmaceutica's ROE % Adjusted to Book Value of 8.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current ROE % Adjusted to Book Value is 8.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.66, compared to a current price of CHF54.70 — trading 5.1% below its estimated fair value. The current ROE % Adjusted to Book Value is 8.04%. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current ROE % Adjusted to Book Value is 8.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF54.70 is trading 5.1% below its estimated GF Value™ of CHF57.66.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
ROE % Adjusted to Book Value: 8.04%
GF Value™: CHF57.66 vs. price of CHF54.70 (5.1% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score
Get the complete analysis for XSWX:BSLN
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
